FDA granted an accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be ...

Ad hoc announcement pursuant to Art. 53 LR Net sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto ...

Novartis’ troubles over the Zolgensma data manipulation incident show no sign of lessening. The company is on the defensive again after it emerged a senior manager sold almost $1 million worth ...

Since 2020, the global SMA treatment landscape has progressed, with three treatments now approved, according to Novartis. Along with Zolgensma – which made its debut in 2019 – Biogen has had ...

The global neurology clinical trials market is poised for substantial growth over the next decade, with projections forecasting an increase in market size from USD 5.7 billion in 2022 to a remarkable ...

Novartis AG engages in the research ... of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis ...

European countries must match ambition with action — and reward the kind of pharmaceutical innovation they say they want to lead.

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

As part of this bold initiative, Novartis will construct and expand ten facilities, including seven entirely new sites. The project is expected to generate nearly 1,000 new jobs directly within ...

Novartis CEO Vas Narasimhan and Sanofi leader Paul Hudson wrote in Britain's Financial Times that European price controls and austerity measures reduce the attractiveness of its markets.

Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG (NOVN – Research Report) on April 24 and set a price target of CHF106.00. The company’s shares closed yesterday at ...